A Diet Low in Red and Processed Meat Does Not Reduce Rate of Crohn’s Disease Flares.

Related Articles

A Diet Low in Red and Processed Meat Does Not Reduce Rate of Crohn’s Disease Flares.

Gastroenterology. 2019 Mar 11;:

Authors: Albenberg L, Brensinger CM, Wu Q, Gilroy E, Kappelman MD, Sandler RS, Lewis JD

Abstract
BACKGROUND & AIMS: Diet may be an important factor in progression of Crohn’s disease (CD). We performed a randomized controlled trial to determine whether reduced consumption of red and processed meats decreases the risk of symptomatic relapse of CD, analyzing results from the Food and Crohn’s Disease Exacerbation Study (FACES) trial.
METHODS: Adults with CD were recruited into the FACES trial from IBD Partners, an internet-based cohort of IBD patients, from November 2013 through June 2015. Individuals who were in remission (CD activity index (sCDAI) scores of 150 or less), had completed a biannual survey, and reported consumption of red meat at least once weekly were randomly assigned to groups that consumed a minimum of 2 servings/week of red or processed meat (high meat, n=118) or not more than 1 serving per month (low meat, n=96) for 49 weeks. The primary outcome was relapse of CD, defined as increase in sCDAI score by ≥70 points and to >150 or a need for CD surgery or new CD medication. A secondary outcome, moderate or severe relapse, was based on an increase in sCDAI to >219 RESULTS: During the trial, the high-meat groups reported consumption of 2 or more servings of red or processed meat during 98.5% of observed weeks compared 18.8% of weeks for the low-meat group. Any and moderate to severe relapse occurred in 62% of participants in the high-meat group and 42% of participants in the low-meat group. There were no significant differences in time to any (P=.61) or moderate/severe (P=.50) relapse.
CONCLUSIONS: In an analysis of data from the FACES trial, we found that among patients with CD in remission, level of red and processed meat consumption was not associated with time to symptomatic relapse. ClinicalTrials.gov Identifier: NCT0192673.

PMID: 30872105 [PubMed – as supplied by publisher]

PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30872105?dopt=Abstract